TrialCancer immunology, immunotherapy : CII2024

Predicting recurrent glioblastoma clinical outcome to immune checkpoint inhibition and low-dose bevacizumab with tumor in situ fluid circulating tumor DNA analysis.

Guangzhong Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.